KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Sundar Jagannath(Mount Sinai Hospital), David S. Siegel(Hackensack Meridian Health), Ajay K. Nooka(Emory University), Kosei Matsue(Kameda Medical Center), Larry D. Anderson(Dana-Farber Cancer Institute), Donna Reece(Princess Margaret Cancer Centre), Kimberly Wilson(Bristol-Myers Squibb (United States)), Nina Shah(The University of Texas MD Anderson Cancer Center), Hartmut Goldschmidt(Heidelberg University), Matthew Streetly(King's College - North Carolina), Paula Rodríguez‐Otero(Clinica Universidad de Navarra), Arlene S. Swern, Yi Lin, Amit Agarwal(Bristol-Myers Squibb (United States)), Hoa Le(Bristol-Myers Squibb (United States)), R Powles(Parkside Hospital), Alicia Senín(Institut Català d'Oncologia)
Cited by 89
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k